340 related articles for article (PubMed ID: 29476013)
1. Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3.
Sowa AS; Martin E; Martins IM; Schmidt J; Depping R; Weber JJ; Rother F; Hartmann E; Bader M; Riess O; Tricoire H; Schmidt T
Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2624-E2633. PubMed ID: 29476013
[TBL] [Abstract][Full Text] [Related]
2. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
3. Disulfiram facilitates ataxin-3 nuclear translocation and potentiates the cytotoxicity in a cell model of SCA3.
Wang Z
J Toxicol Sci; 2019; 44(8):535-542. PubMed ID: 31378764
[TBL] [Abstract][Full Text] [Related]
4. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
5. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons.
Li YX; Sibon OCM; Dijkers PF
J Neuroinflammation; 2018 Sep; 15(1):261. PubMed ID: 30205834
[TBL] [Abstract][Full Text] [Related]
7. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
[TBL] [Abstract][Full Text] [Related]
8. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
9. Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3.
Johnson SL; Libohova K; Blount JR; Sujkowski AL; Prifti MV; Tsou WL; Todi SV
Neurobiol Dis; 2021 Dec; 160():105516. PubMed ID: 34563642
[TBL] [Abstract][Full Text] [Related]
10. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
Raj K; Akundi RS
Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
Sutton JR; Blount JR; Libohova K; Tsou WL; Joshi GS; Paulson HL; Costa MDC; Scaglione KM; Todi SV
Hum Mol Genet; 2017 Apr; 26(8):1419-1431. PubMed ID: 28158474
[TBL] [Abstract][Full Text] [Related]
12. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
13. Differential toxicity of ataxin-3 isoforms in Drosophila models of Spinocerebellar Ataxia Type 3.
Johnson SL; Blount JR; Libohova K; Ranxhi B; Paulson HL; Tsou WL; Todi SV
Neurobiol Dis; 2019 Dec; 132():104535. PubMed ID: 31310802
[TBL] [Abstract][Full Text] [Related]
14. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
Chen ZS; Huang X; Talbot K; Chan HYE
Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
[TBL] [Abstract][Full Text] [Related]
15. KPNB1 modulates the Machado-Joseph disease protein ataxin-3 through activation of the mitochondrial protease CLPP.
Abeditashi M; Weber JJ; Pereira Sena P; Velic A; Kalimeri M; Incebacak Eltemur RD; Schmidt J; Hübener-Schmid J; Hauser S; Macek B; Riess O; Schmidt T
Cell Mol Life Sci; 2022 Jul; 79(8):401. PubMed ID: 35794401
[TBL] [Abstract][Full Text] [Related]
16. Vulnerability of frontal brain neurons for the toxicity of expanded ataxin-3.
Schmidt J; Mayer AK; Bakula D; Freude J; Weber JJ; Weiss A; Riess O; Schmidt T
Hum Mol Genet; 2019 May; 28(9):1463-1473. PubMed ID: 30576445
[TBL] [Abstract][Full Text] [Related]
17. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models.
Hübener J; Riess O
Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840
[TBL] [Abstract][Full Text] [Related]
18. The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits.
Koppenol R; Conceição A; Afonso IT; Afonso-Reis R; Costa RG; Tomé S; Teixeira D; da Silva JP; Côdesso JM; Brito DVC; Mendonça L; Marcelo A; Pereira de Almeida L; Matos CA; Nóbrega C
Brain; 2023 Jun; 146(6):2346-2363. PubMed ID: 36511898
[TBL] [Abstract][Full Text] [Related]
19. Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3.
Costa MDC; Ashraf NS; Fischer S; Yang Y; Schapka E; Joshi G; McQuade TJ; Dharia RM; Dulchavsky M; Ouyang M; Cook D; Sun D; Larsen MJ; Gestwicki JE; Todi SV; Ivanova MI; Paulson HL
Brain; 2016 Nov; 139(11):2891-2908. PubMed ID: 27645800
[TBL] [Abstract][Full Text] [Related]
20. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.
Paulino R; Nóbrega C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]